- Conditions
- Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
- Interventions
- BGJ398, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1991
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Myoclonus Epilepsies, Progressive
- Interventions
- AUT00201, Placebo
- Drug
- Lead sponsor
- Autifony Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Smallpox, Atopic Dermatitis
- Interventions
- MVA (smallpox vaccine)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- PTC124
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
- Interventions
- RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
- Drug
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 7
- States / cities
- Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
- Conditions
- Solid Tumor
- Interventions
- ASP4396
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more
- Conditions
- Solid Tumor
- Interventions
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
- Conditions
- Gout, Cardiovascular Diseases
- Interventions
- Not listed
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 24,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Tourette Syndrome, Tic Disorders
- Interventions
- Comprehensive Behavioral Intervention for Tics
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Solid Tumors, GI Cancer
- Interventions
- CGX1321, Pembrolizumab, encorafenib, cetuximab
- Drug
- Lead sponsor
- Curegenix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 25
- States / cities
- Long Beach, California • Santa Rosa, California • Denver, Colorado + 21 more
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
- Interventions
- ELI-002 2P
- Drug
- Lead sponsor
- Elicio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Advanced Solid Tumor
- Interventions
- MRTX849, Palbociclib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
- Interventions
- Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Metastatic Colorectal Cancer, KRAS Gene Mutation
- Interventions
- Onvansertib, Bevacizumab, FOLFIRI
- Drug · Biological
- Lead sponsor
- Cardiff Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 4 more
- Conditions
- Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Elacestrant, DC1 native/mutated ESR1
- Drug · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- AEB071
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Duarte, California • St Louis, Missouri • Hackensack, New Jersey + 3 more
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
- Interventions
- APL-101 Oral Capsules
- Drug
- Lead sponsor
- Apollomics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more
- Conditions
- Multiple Myeloma, Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Sedona, Arizona • Tucson, Arizona • Burbank, California + 15 more
- Conditions
- Breast Cancer
- Interventions
- REDS survey
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 39 Years to 49 Years · Female only
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
- Interventions
- Bevacizumab, Niraparib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Charlottesville, Virginia